Compare SGML & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGML | SNDX |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2021 | 2014 |
| Metric | SGML | SNDX |
|---|---|---|
| Price | $5.82 | $9.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $10.33 | ★ $35.45 |
| AVG Volume (30 Days) | 2.7M | ★ 3.5M |
| Earning Date | 11-11-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $172,352,000.00 |
| Revenue This Year | $58.22 | $83.56 |
| Revenue Next Year | $138.88 | $45.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 627.84 |
| 52 Week Low | $4.99 | $9.99 |
| 52 Week High | $24.48 | $25.59 |
| Indicator | SGML | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 32.38 | 25.89 |
| Support Level | N/A | N/A |
| Resistance Level | $10.50 | $25.38 |
| Average True Range (ATR) | 0.63 | 1.03 |
| MACD | -0.20 | -0.28 |
| Stochastic Oscillator | 21.95 | 5.76 |
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds full interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil. Geographically, the company operates in Switzerland; United Arab Emirates; Singapore; and Republic of Korea, of which it derives maximum revenue from Switzerland.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.